От синдрома к болезни: эволюция номенклатуры болезни Шегрена
https://doi.org/10.14412/1996-7012-2025-6-7-12
Аннотация
В статье рассматриваются современные представления о болезни Шегрена как самостоятельном мультисистемном аутоиммунном заболевании с широким спектром органных проявлений и высоким риском лимфопролиферативных осложнений. Особое внимание уделяется новым данным о патогенетических механизмах, в основе которых лежит гиперактивность B-клеток. Обсуждаются самые передовые подходы к мониторингу и лечению, включая внедрение индексов активности и перспективы таргетного лечения.
Ключевые слова
болезнь Шегрена,
«первичный синдром» Шегрена,
«ассоциированная» болезнь Шегрена,
системность,
гиперактивность В-клеток
При поддержке: Исследование не имело спонсорской поддержки
Об авторах
А. Л. Маслянский
ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России; ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ВО «Санкт-Петербургский государственный университет»
Россия
Россия
197341, Санкт-Петербург, ул. Аккуратова, 2; 115522, Москва, Каширское шоссе, 34А; 199034, Санкт-Петербург, Университетская наб., 7–9
А. В. Торгашина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Анна Васильевна Торгашина
115522, Москва, Каширское шоссе, 34А
Литература
1. Jonsson R. Henrik Sjögren (1899-1986): the syndrome and his legacy. Ann Rheum Dis. 2021 Sep;80(9):1108-1109. doi: 10.1136/annrheumdis-2021-219942.
2. Moutsopoulos HM, Mann DL, Johnson AH, Chused TM. Genetic differences between primary and secondary sicca syndrome. N Engl J Med. 1979 Oct 4;301(14):761-3. doi: 10.1056/NEJM197910043011405.
3. Björk A, Mofors J, Wahren-Herlenius M. Environmental factors in the pathogenesis of primary Sjögren's syndrome. J Intern Med. 2020 May;287(5):475-492. doi: 10.1111/joim.13032.
4. Beydon M, McCoy S, Nguyen Y, et al. Epidemiology of Sjögren syndrome. Nat Rev Rheumatol. 2024 Mar;20(3):158-169. doi: 10.1038/s41584-023-01057-6.
5. Baer AN, Hammitt KM. Sjögren’s disease, not syndrome. Arthritis Rheumatol. 2021 Jul; 73(7):1347-1348. doi: 10.1002/art.41676.
6. Ramos-Casals M, Baer AN, Brito-Zerуn MDP, et al. 2023 International Rome consensus for the nomenclature of Sjögren disease. Nat Rev Rheumatol. 2025 Jul;21(7): 426-437. doi: 10.1038/s41584-025-01268-z.
7. Mavragani CP, Moutsopoulos HM. Primary versus secondary Sjögren syndrome: is it time to reconsider these terms? J Rheumatol. 2019 Jul;46(7):665-666. doi: 10.3899/jrheum.180392.
8. Baldini C, Bartoloni E, Bombardieri M. Highlights of the 15th international symposium on Sjögren’s syndrome. Clin Exp Rheumatol. 2022 Dec;40(12):2201-2210. doi: 10.55563/clinexprheumatol/yt6g9t.
9. Baldini C, Chatzis LG, Fulvio G, et al. Pathogenesis of Sjögren's disease: one year in review 2024. Clin Exp Rheumatol. 2024 Dec; 42(12):2336-2343. DOI: 10.55563/clinex-prheumatol/i8iszc.
10. Liu Z, Chu A. Sjögren’s Syndrome and Viral Infections. Rheumatol Ther. 2021 Sep;8(3): 1051-1059. doi: 10.1007/s40744-021-00334-8.
11. Li L, Shen S, Shao S, et al. The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances. Front Immunol. 2025 Jun 6:16:1538555. doi: 10.3389/fimmu.2025.1538555.
12. Пономарев АБ, Пашаева КР, Фейзиева НЮ. Сравнительный анализ механизмов развития криоглобулинемического васкулита и синдрома Шегрена. Архив патологии. 2024;86(1):52 56.
13. Verstappen GM, Kroese FGM, Bootsma H, et al. T cells in primary Sjögren's syndrome: targets for early intervention.Rheumatology(Oxford). 2021 Jul 1;60(7):3088 3098. doi: 10.1093/rheumatology/kez004.
14. Lessard C J, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren’s syndrome. Nat Genet. 2013 Nov; 45(11):1284-1292. doi: 10.1038/ng.2792.
15. Khatri B, Tessneer KL, Rasmussen A, et al. Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells. Nat Commun. 2022 Jul 26;13(1):4287. doi: 10.1038/s41467-022-30773-y.
16. Thorlacius GE, Hultin-Rosenberg L, Sandling JK, et al. Genetic and clinical basis for two distinct subtypes of primary Sjögren’s syndrome. Rheumatology (Oxford). 2021 Feb 1; 60(2):837-848. doi: 10.1093/rheumatology/keaa331.
17. Thorlacius GE, Bjork A, Wahren-Herlenius M. Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies. Nat Rev Rheumatol. 2023 May; 19(5):288-306. doi: 10.1038/s41584-023-00932-6.
18. Bootsma H, Kroese FGM. Association of Circulating Antibody-Secreting Cell Maturity With Disease Features in Primary Sjögren’s Syndrome. Arthritis Rheumatol. 2023 Jun; 75(6):973-983. doi: 10.1002/art.42422.
19. Baldini C, Fulvio G, La Rocca G, Ferro F. Update on the pathophysiology and treatment of primary Sjögren syndrome. Nat Rev Rheumatol. 2024 Aug;20(8):473-491. doi: 10.1038/s41584-024-01135-3.
20. Meudec L, Debray MP, Beurnier A, et al. Pulmonary involvement in Sjögren syndrome. RMD Open. 2024 Feb 29;10(1): e003866. doi: 10.1136/rmdopen-2023003866.
21. Madej M, Proc K, Wawryka P, et al. The analysis of the pulmonary domain involvement in Sjögren's disease. Ther Adv Musculoskelet Dis. 2024 Dec 16:16:1759720 X241305218. doi: 10.1177/1759720X24 1305218.
22. Чальцев БД, Васильев ВИ, Аветисов ИО и др. Поражение респираторного тракта при болезни Шёгрена, фокус на интерстициальное заболевание легких. Научно-практическая ревматология. 2022;60(2):214-227.
23. Aiyegbusi O, McGregor L, McGeoch L, et al. Renal Disease in Primary Sjögren’s Syndrome. Rheumatol Ther. 2020 Dec 24;8(1): 63–80. doi: 10.1007/s40744-020-00264-x.
24. Porto Fuentes У. Renal involvement in primary Sjögren's syndrome: Beyond tubulointerstitial nephritis. Nefrologia (Engl Ed). 2025 Aug-Sep;45(7):501341. doi: 10.1016/j.nefroe.2025.501341.
25. Barsottin OGP, de Moraes MPM, Fraiman PHA, et al. Sjögren's syndrome: a neurological perspective. Arq Neuropsiquiatr. 2023 Dec 29;81(12):1077–1083. doi: 10.1055/s-0043-1777105.
26. Breillat P, Le Guern V, d'Humieres T, et al. Cutaneous Vasculitis in Primary Sjögren Disease. JAMA Dermatol. 2025 Aug 6;161(10): 1057-62. doi: 10.1001/jamadermatol.2025.2665.
27. Торгашина АВ. Современный взгляд на лечение болезни Шегрена. Фарматека. 2020; 27(7):72 80.
28. Васильев МИ, Пробатова НА, Тупицын НН и др. Лимфопролиферативные заболевания при болезни Шегрена. Онкогематология. 2007;(3):16-26.
29. Rusinovich-Lovgach O, Plaza Z, Fernandez-Castro M, el al. High incidence of lymphoma in Sjögren's disease: predictors and mortality implications in a prospective cohort study. Rheumatol Int. 2025 Aug 6;45(8):184. doi: 10.1007/s00296-025-05935-y.
30. Shetler K. Management of Gastrointestinal Manifestations in Sjцgren’s. In: Wallace DJ, editor. The Sjögren's Book 5. Oxford: Oxford University Press; 2022. P. 331–337.
31. Brito-Zerуn P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sjögren syndrome: Predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2016 Feb;75(2):348-55. doi: 10.1136/annrheumdis-2014-206418.
32. Duarte C, Ferreira RJO, Santos EJF, da Silva JAP. Treating-to-target in rheumatology: Theory and practice. Best Pract Res Clin Rheumatol. 2022 Mar;36(1):101735. doi: 10.1016/j.berh.2021.101735.
33. Brito-Zerуn P, Ramos-Casals M, Benga G, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome. RMD Open. 2019 Oct 28;5(2):e001064. doi: 10.1136/rmdopen-2019-001064.
34. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis. 2010 Jun;69(6): 1103-9. doi: 10.1136/ard.2009.110619.
35. Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015 Feb 20;1(1):e000022. doi: 10.1136/rmdopen-2014-000022.
36. Ture HY, Kim NR, Nam EJ. EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and Other Patient-Reported Outcomes in the Assessment of Glandular Dysfunction in Primary Sjögren's Syndrome. Life (Basel). 2023 Sep 29;13(10):1991. doi: 10.3390/life13101991.
37. Isenberg DA. CRESS: improving the assessment of disease activity in Sjögren's syndrome. Lancet Rheumatol. 2021 Aug;3(8): e534-e535. doi: 10.1016/S2665-9913(21)00150-8.
38. Fox PC, Datiles M, Atkinson JC, Macynski AA, et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol. 1993 Mar-Apr;11(2):149-156.
39. Gottenberg JE, Ravaud P, Puechal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome the JOQUER randomized clinical trial. JAMA. 2014 Jul 16;312(3):249-58. doi: 10.1001/jama.2014.7682.
40. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren’s syndrome. Clin Exp Rheumatol. 1996 Sep-Oct;14(5):555-558.
41. Price E, Rigby S, Clancy U, Venables PA. Double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren’s syndrome. J Rheumatol. 1998 May; 25(5):896-9.
42. Felten R, Devauchelle-Pensec V, Seror R, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2021 Mar;80(3):329-338. doi: 10.1136/annrheumdis-2020-218467.
43. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004 Apr;50(4):1270-6. doi: 10.1002/art.20146.
44. Baer AN, Gottenberg JE, E St Clair W, et al. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. Ann Rheum Dis. 2021;80(3):339-348. doi: 10.1136/annrheumdis-2020-218599.
45. Meletis J, Gottenberg JE, Mariette X, et al. Efficacy of Rituximab in Primary Sjögren’s Syndrome: The TEARS Randomized, Placebo-Controlled Trial. Ann Intern Med. 2014 Feb 18;160(4):233-42. doi: 10.7326/M13-1085.
46. Ritter J, Chen Y, Stefansk AL, Dörner T. Current and future treatment in primary Sjögren's syndrome – A still challenging development. Joint Bone Spine. 2022 Nov;89(6): 105406. doi: 10.1016/j.jbspin.2022.105406.
47. De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. Rheumatology (Oxford). 2015 Dec;54(12):2249-56. doi: 10.1093/rheumatology/kev257.
48. Mariette X, Barone F, Baldini C, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome. JCI Insight. 2022 Dec 8;7(23): e163030. doi: 10.1172/jci.insight.163030.
49. Dörner T, Posch MG, Li Y, et al. Treatment of primary Sjögren's syndrome with ianalumab, an anti-BAFF receptor monoclonal antibody. Ann Rheum Dis. 2019 May; 78(5):641-647. doi: 10.1136/annrheumdis-2018-214720.
50. Bowman SJ, Everett CC, O'Dwyer JL, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0.
51. Dörner T, Bowman SJ, Fox R, et al. Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study. Arthritis Rheumatol. 2025 May;77(5):560-570. doi: 10.1002/art.43059.
52. Gottenberg JE, Sivils K, Campbell K, et al. Efficacy and Safety of nipocalimab, an antiFcRn monoclonal antibody, in primary Sjögren’s disease: Results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS). Ann Rheum Dis. 2024;83(1):240.
Рецензия
Для цитирования:
Маслянский АЛ, Торгашина АВ. От синдрома к болезни: эволюция номенклатуры болезни Шегрена. Современная ревматология. 2025;19(6):7-12. https://doi.org/10.14412/1996-7012-2025-6-7-12
For citation:
Maslyansky AL, Torgashina AV. From syndrome to disease: the evolution of the nomenclature of Sjögren’s disease. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(6):7-12. (In Russ.) https://doi.org/10.14412/1996-7012-2025-6-7-12
Просмотров:
54
Послать статью по эл. почте 